Palo Alto, Calif.-based startup Doc.ai is training its sights on the $9.5 billion global epilepsy market, with the aim of using artificial intelligence to help patients find the best medication to control their seizures. To that end, the company is teaming up with the Stanford University School of Medicine and the Stanford Epilepsy Center on a digital health trial to develop a predictive treatment model that will identify the right treatment at the right time for individuals living with epilepsy.
According to the U.S. Epilepsy Foundation, one in 26 people in the country will develop epilepsy at some point in their lives and the condition is the fourth most common neurological disease that affects people of all ages. That is why the current anti-epilepsy drug therapy market is large and estimated to be worth more than $8.5 billion currently, rising to in excess of $9.5 billion in five years.
